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Abstract
Background: Invasive meningococcal disease is a significant cause of mortality and morbidity in
the UK. Administration of chemoprophylaxis to close contacts reduces the risk of a secondary
case. However, unnecessary chemoprophylaxis may be associated with adverse reactions,
increased antibiotic resistance and removal of organisms, such as Neisseria lactamica, which help to
protect against meningococcal disease. Limited evidence exists to suggest that overuse of
chemoprophylaxis may occur. This study aimed to evaluate prescribing of chemoprophylaxis for
contacts of meningococcal disease by general practitioners and hospital staff.
Methods: Retrospective case note review of cases of meningococcal disease was conducted in one
h e a l t h  d i s t r i c t  f r o m  1 st September 1997 to 31st August 1999. Routine hospital and general
practitioner prescribing data was searched for chemoprophylactic prescriptions of rifampicin and
ciprofloxacin. A questionnaire of general practitioners was undertaken to obtain more detailed
information.
Results: Prescribing by hospital doctors was in line with recommendations by the Consultant for
Communicable Disease Control. General practitioners prescribed 118% more chemoprophylaxis
than was recommended. Size of practice and training status did not affect the level of additional
prescribing, but there were significant differences by geographical area. The highest levels of
prescribing occurred in areas with high disease rates and associated publicity. However, some true
close contacts did not appear to receive prophylaxis.
Conclusions:  Receipt of chemoprophylaxis is affected by a series of patient, doctor and
community interactions. High publicity appears to increase demand for prophylaxis. Some true
contacts do not receive appropriate chemoprophylaxis and are left at an unnecessarily increased
risk.
Background
Invasive meningococcal disease is a significant cause of
morbidity and mortality in the United Kingdom and the
commonest infectious cause of death under the age of
20[1]. In 1999 almost 3000 cases were notified with an
overall case fatality rate of around 8%[2]. There is an in-
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creased risk of a secondary case of meningococcal disease
amongst household contacts, which is between 450 and
1650 times that of the general population [3–6]. This is in
part explained by the fact that household and kissing con-
tacts frequently carry the same pathogenic strain[7].
Chemoprophylaxis is given to close contacts of cases to
eliminate naso-pharyngeal carriage of meningococci.
Prophylaxis reduces, but does not eliminate, the risk of
secondary cases[8]. If prophylaxis is not given to appropri-
ate contacts then preventable secondary cases may occur.
Unnecessary use of prophylaxis is associated with in-
creased antibiotic resistance, drug side effects, and remov-
al of non-virulent meningococci and N. lactamica; both
organisms induce immunity and provide a competitive
flora against colonisation with virulent meningococcal
strains [9–11].
UK guidelines identify who should receive prophylaxis
[12], and in this study we evaluate the prescribing of
prophylaxis by hospital staff and general practitioners
against these criteria.
Methods
All confirmed and clinical cases [13] of invasive meningo-
coccal disease amongst residents of Southern Derbyshire
Health Authority between 1st September 1997 and 31st
August 1999 were identified from the Notifications of In-
fectious Diseases database and data from the enhanced
surveillance of meningococcal infections undertaken by
the Communicable Disease Surveillance Centre, Trent.
Data on contacts identified at the time were obtained
from the Consultant for Communicable Disease Control's
(CCDC) records and were assessed against the current UK
guidelines [12]. Data were recorded regarding the method
of contact tracing (face to face or by telephone, and by
whom if face to face contact had taken place), whether the
case was confirmed by laboratory investigations, the sero-
group of identified organisms and the number of contacts
identified.
General practitioner prescribing data from Prescribing
Analysis and Cost (PACT) for 1st September 1997 to 31st
August 1999 were examined to identify possible chemo-
prophylactic prescriptions for rifampicin, ciprofloxacin
and ceftriaxone. Hospital dispensing data for rifampicin
(the only drug used for chemoprophylaxis in the hospital
protocol during this period) were examined for the period
1st March 1999 to 31st August 1999. Computerised data
were not available before 1st March 1999.
All 2-day courses of rifampicin were assumed to be for
eradication of meningococcal carriage[14]. Ciprofloxacin
is widely used in general practice, but the only indications
for single dose treatment in the British National Formu-
lary are gonorrhoea and chemoprophylaxis for meningo-
coccal disease[15]. All prescriptions for single dose
ciprofloxacin were assumed to be for prophylaxis. The
same assumption was made for single 250 mg doses of
ceftriaxone.
As PACT data do not identify individual patients a ques-
tionnaire was sent to all GP practices in Southern Derby-
shire. This covered the use of rifampicin, ciprofloxacin
and ceftriaxone for prophylaxis during the study period.
The questionnaire also requested the initials of the con-
tact, the initials of the index case for the contact, the drug
prescribed and the date of the prescription. Practices were
free to obtain the information by whatever method they
felt was most effective in the context of their own practice.
This information was linked with the database of cases
and contacts to identify which contacts had been pre-
scribed prophylaxis. Practices were also given the option
to indicate if they were unable to retrieve the relevant data.
For those who had received a prescription, an assessment
was made and they were classified into one of the follow-
ing groups:
• known to the CCDC and prophylaxis recommended
• known to the CCDC, related to a known case of menin-
gococcal disease, but prophylaxis not recommended
• not known to the CCDC but related in time and place to
a known case, and
• known to the CCDC and not related to a known case of
meningococcal disease in the district.
Statistics
Student's t tests on log transformed data were used to
compare the mean number of contacts per case by sero-
group, whether confirmed or clinical case and method of
contact tracing. The Mann Whitney U test was used to
compare the level of additional prescribing per GP for
each practice by response status to questionnaire and
training status of the practice. The relationship between
the size of the practice and the number of additional pre-
scriptions per GP was explored by using Spearman rank
correlation. Mann Whitney U test was used to determine
differences between the levels of additional prescribing at
local authority level. Linear regression was used to explore
any possible relationships between the level of additional
prescribing at Local Authority level and the Towsnend
deprivation score and rate of invasive meningococcal dis-
ease.BMC Public Health 2001, 1 http://www.biomedcentral.com/1471-2458/1/16
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Results
During the study period 134 cases (66 male, 68 female) of
meningococcal disease were notified. Of these 88 (66%)
were confirmed by laboratory diagnosis and 46 (34%)
were clinical cases. Of the 75 that were groupable, 50
(67%) were serogroup B, 24 (32%) were serogroup C and
1 (1%) was serogroup Y.
The population estimate for 1998 for Southern Derby-
shire was 567,457. The rate of confirmed meningococcal
disease was 7.8 per 100,000 per annum. The rate of clini-
cal and confirmed cases[13] was 11.8 per 100,000 per an-
num compared to the England and Wales rate in 1998 of
6.1/100,000 (rate ratio 1.9, 95% CI 1.5–2.5, p < 0.0001)
Contact tracing
In 34 (25%) cases the patient or other key informants
were interviewed in person by the CCDC, in 24 (18%) by
another public health physician and in 51 (38%) cases
contact tracing was performed by telephone. In 25 (18%)
of cases it was impossible to determine the method of
contact tracing.
952 close contacts were identified for whom prophylaxis
had been recommended by a public health physician. The
mean number of contacts per case was 7.2 and the median
6.0. The mean number of contacts for each case visited by
a public health physician was 6.4 and for each case where
contact tracing was done by telephone was 8.3 (Students t
test on log transformed data, p = 0.03). There were no sig-
nificant differences in the mean number of contacts per
case by serogroup, by whether face to face contact tracing
was performed by the CCDC or a public health physician
in training, nor by whether the case was confirmed by lab-
oratory investigations or not.
The degree of contact with the index case was determined
for 697 (73.2%) of the contacts as shown in Table 1.
Prescribing
For 568 (60%) contacts chemoprophylaxis was prescribed
by hospital staff and for 296 (31%) the general practition-
er (GP) was asked to prescribe. For 88 (9%) contacts the
prescriber was unspecified.
During the six month period for which hospital prescrib-
ing data were available, 69 prescriptions were identified
from the dispensing records. Of these 11 were for the
elimination of carriage in cases. A further five were con-
tacts where chemoprophylaxis was not recommended and
in one instance the prescription might have related to one
of three recent cases, but the contact had not been identi-
fied by the CCDC. For six identified contacts no record
could be found that the prescription had been dispensed,
although for two of these the GP had prescribed.
Of the 296 contacts for whom GPs were asked to pre-
scribe, 277 were patients of GPs in Southern Derbyshire.
604 prescriptions for chemoprophylaxis were identified
from the PACT data, 327 (118%) more than recommend-
ed by the CCDC. The rates of disease and number of addi-
tional prescriptions per GP for each local authority area
are shown in Table 2. No association could be demon-
strated by linear regression between the mean number of
additional prescriptions per GP for each local authority
area and the rate of invasive disease (p = 0.30) or
Townsend deprivation score (p = 0.72). The two areas
with high rates of disease (including clusters), and subse-
quent publicity both had significantly higher prescribing
The other large authority with high rates of disease, but lit-
tle publicity, had a significantly lower level of additional
prescribing.
At a practice level, there were no significant differences in
estimated additional prescribing by response status to
questionnaire, training status or size of practice.
GP Questionnaires
Fifty-seven out of 80 practices (71%) replied to the ques-
tionnaire. Of these, 17 (21% of all practices) were unable
to supply data. Data was therefore obtained from 40
(50%). Chemoprophylaxis was recommended for 142
identified contacts who were patients of these practices
whilst the practices identified 179 chemoprophylaxis pre-
scriptions.
Figure 1 shows whether or not a record of prescribing ex-
isted for the contacts who had been recommended to have
prophylaxis. Figure 2 shows how many of the recorded
prescriptions for chemoprophylaxis had been recom-
mended.
In these practices, PACT identified a total of 305 courses
of chemoprophylaxis and GP practices identified 179. The
number of prescriptions for rifampicin, ciprofloxacin and
Table 1: Nature of contact.
Nature of contact Number (%)
Household 442 (63)
Overnight stay in past 7 days 71 (10)
Childminding 20 (3)
Kissing (saliva exchange) 19(3)
Resuscitation 1(0)
Other contact (>8 hours) 40 (6)
Other contact (<8 hours) 104(15)
TOTAL 697(100)BMC Public Health 2001, 1 http://www.biomedcentral.com/1471-2458/1/16
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ceftriaxone are shown in Table 3. There is no difference
between the ratio of prescriptions recorded by GPs be-
tween rifampicin and ciprofloxacin.
Discussion
This study demonstrated that after a case of invasive
meningococcal disease, more prescriptions for chemo-
prophylaxis are dispensed than would be expected from a
strict interpretation of the United Kingdom guidelines
[12]. However, some people who are at increased risk ap-
pear not to receive prophylaxis. No practice characteristics
examined accounted for differences in additional pre-
scribing between practices, nor did the rate of invasive
meningococcal disease or the level of social deprivation in
the local authority areas. However, it is plausible that sig-
nificant levels of publicity in the two areas with highest
levels of additional prescribing may have increased re-
quests to GPs to prescribe prophylaxis.
There are a number of possible limitations of this study.
Firstly, contact ascertainment may be incomplete. Not all
recommendations for prophylaxis may be recorded and it
was not always possible to ascertain the degree of contact
from the records. Secondly, questionnaire data from prac-
tices were incomplete. These practices may not be repre-
sentative. However, the fact that the numbers of
additional prescriptions per GP were similar for respond-
ers and non-responders suggests that this has not affected
the results.
The mean number of contacts per case of meningococcal
disease in our study was similar to that found in other
studies in the UK[14,16]. Significantly less close contacts
were identified when a public health physician conducted
a face to face interview with the key informants. This sug-
gests that contact tracing is more appropriate with less un-
necessary prophylaxis given when informants are
interviewed personally. It is, however, possible that there
may be a confounding effect between the use of telephone
interviews and experience at contact tracing. However,
where face to face interviews took place there was no sig-
nificant difference between the number of contacts iden-
tified by the CCDC and public health doctors in training.
There were significant discrepancies between the numbers
of prescriptions recorded by PACT and those identified by
the practices. PACT is an accurate record of prescriptions
dispensed by community pharmacies. Short courses of ri-
fampicin have no other indication, so it is likely that these
are for chemoprophylaxis[14]. By contrast, single dose
courses of ciprofloxacin are indicated for the treatment of
gonorrhoea. However, less than 10 isolates of Neisseria
gonorrhoeae come from general practice in the district each
year. [D Bullock, personal communication] Most of these
will be referred to the genito-urinary medicine service.
Even if they were all treated in general practice the differ-
ence this would make to the overall results presented here
would be small. If significant amounts of single dose cip-
rofloxacin were being used for indications other than che-
moprophylaxis, then the ratio of PACT prescriptions to
those recorded by GPs would be higher for ciprofloxacin
than for rifampicin. As this was not the case, it is likely
that most single dose courses were for chemoprophylaxis
of meningococcal disease.
The data provided by general practices may have underes-
timated the prescribing of chemoprophylaxis. Prescrip-
tions may not be recorded in the records, may not be
entered on the computer system or may not be retrieved
during a search. This may be a particular problem if the
Table 2: Rates of meningococcal disease and additional prescriptions per GP (from PACT data) by local authority area
Local Authority
1* 23 4 * 5
Cases of meningococcal disease 34 62 1 28 9
Population 125727 258919 37091 103735 67655
Townsend deprivation score -1.56 2.09 -2.97 -0.79 -3.01
Rate of IMD per 100,000 13.5 12.0 1.3 13.5 6.7
Number of practices 16 38 4 14 9
Mean number of additional prescriptions per GP (SD) 2.2(3.1) 0.2(1.4) 0.5 (0.5) 1.9(1.1) 0.9(0.8)
Median number of additional prescriptions per GP 
(interquartile range)
1.2 (0.5–3.3) 0.0 (0.0–0.8) 0.5 (0.0–0.9) 1.91 (0.9–2.6) 0.7 (0.3–1.6)
Difference in mean number of additional prescriptions per GP for 
each Local Authority compared to all others. P (two tailed)
0.02 <0.001 0.6 0.002 0.8
*represents high publicity areaBMC Public Health 2001, 1 http://www.biomedcentral.com/1471-2458/1/16
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patient is attended by an out of hours service. Although
these prescriptions will be attributed to the practice the
patient is registered with on PACT, the correspondence
from the out of hours service may not find its way into the
main patient record or may not be computerised. It is
therefore likely that the data from the GP questionnaires
underestimated the true level of prescribing.
Hospital prescribing was in line with the recommenda-
tions of the CCDC. However, we found that GPs had pre-
scribed twice as many courses of prophylaxis (from PACT
data) as recommended. The additional prescribing must
be for one of the following reasons:
• for true close contacts who have been missed by the
CCDC, which, although possible is unlikely
• for contacts of cases in other districts. In this study only
5% of recommendations were to GPs in other districts. It
is likely that the reverse is also true, so this could account
for only a small proportion of additional prescriptions.
• for people whose degree of contact does not warrant
prophylaxis
• for contacts of patients who do not have meningococcal
disease (e.g. contacts of people who are perceived by the
public to have meningococcal disease, but in fact have an-
other disease). For this to occur the GP would be required
to prescribe prophylaxis solely on the word of the patient.
Many GPs would consult the Public Health Department
in this situation, which would lead to the recognition of
cases of meningitis or reassurance that it was not menin-
gococcal disease.
It is impossible from the data available to further assess
the nature of this additional prescribing, but it is probable
that it results from a combination of the suggested possi-
bilities.
A UK study in 1995 [14] showed over-prescribing by a fac-
tor of three, although this only used PACT data and did
not include hospital data or obtain further information
from GPs. This approach may overestimate prescribing
and almost certainly include some appropriate prescrip-
tions. An audit from Denmark[17] also found that unnec-
essary prophylaxis was prescribed. The mean "over-
treatment" in the Danish study was 0.9 person/case (in
our study 2.4 persons/case). The Danish study inter-
viewed an adult associated with each case and also identi-
fied 0.4 missed contacts per case. Our methodology did
not allow this comparison to be performed. Conversely,
their methods were likely to underestimate the level of ad-
ditional prescribing because the informant may not know
about prescriptions supplied outside the immediate
household.
Over-prescribing varied by local authority area and was
significantly higher in two areas. Practices in local author-
ity areas 1 and 4 wrote significantly more additional pre-
scriptions than average. Both these areas had high levels of
disease with local publicity surrounding clusters and indi-
vidual cases. In the other area (2) with a similarly high
rate of disease levels of publicity were much lower. No ev-
idence of an association between over prescribing and
rates of invasive meningococcal disease or social depriva-
tion could be found. We speculate that the high publicity
levels resulted in higher levels of demand for chemo-
prophylaxis from people who were associated with the
cases, but not true close contacts. This is supported by a
Figure 1
Outcome of recommendations for chemoprophylaxis from
GP questionnaires
142 contacts
recommended
prophylaxis
80 (56%) have record
of prescription in
GP practice
62 (44%) have no record
of prescription in
GP practice
Figure 2
Analysis of prescriptions written by GP practices from GP
questionnaires
179 (100%)
prescriptions for chemoprophylaxis
identified by GP practices
96 (54%)
recommended
by CCDC
83 (46%) not
recommended
by CCDC
8 (4%)
hospital
asked to
prescribe,
but GP
provided
instead
3 (2%)
contacts
of cases
outside
district
85 (47%)
GP asked
to prescribe
64 (36%)
case of IMD in
district in
preceding 7 days,
but not identified
as a close contact
19 (11%) no
case of IMD in
district in
preceding 7 daysBMC Public Health 2001, 1 http://www.biomedcentral.com/1471-2458/1/16
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lower rate of prescribing in the other high disease rate ar-
ea. This area (2) has no discrete communities in which
clusters of disease have been identified and the public did
not react in the same way as in the other two, more rural,
areas. This over-prescribing is likely to be patient driven,
as GPs do not actively seek inappropriate contacts to treat.
On almost 50% of occasions that GPs were asked to pre-
scribe, there is no record within the practice that the pre-
scription was written. There are a number of possible
explanations for this. Firstly, prescriptions may not have
been written, leaving some people at an unnecessarily in-
creased risk of disease. This is supported by the fact that 10
out of 80 practices prescribed less according to PACT data
than the number of courses recommended. Secondly, pre-
scriptions may have been issued but no record kept which
has implications for clinical governance. If the patient is
attended by the out of hours service, the prescription may
have been written but the information not transferred to
the main general practice record or not entered on the
practice computer system. Even if the GP has written a pre-
scription the contact may still not have received prophy-
laxis. It is possible that some contacts did not come
forward to receive their prescription or did not present it
to a pharmacy. The prescription charge may have acted as
a deterrent. Other contacts may have found that ri-
fampicin was not immediately available at the pharmacy
and consequently did not return to collect their antibiot-
ics. Further work is necessary to elucidate the extent to
which these barriers may operate.
Conclusions
Receipt of chemoprophylaxis is affected by a series of pa-
tient, doctor and community interactions. Additional pre-
scribing occurs at all stages in the process. High publicity
appears to increase demand, although a significant
number of contacts appear never to receive a cost-effective
treatment. Our study also raises issues about the quality of
documentation on the identification and subsequent sup-
ply of antibiotics to contacts. Further research is required
to elucidate the reasons why some contacts seem not to re-
ceive prophylaxis.
A number of steps could be taken to ensure that use of
chemoprophylaxis is as appropriate as possible. Face to
face interviews with key informants by public health prac-
titioners may help to prevent overprescribing. Further re-
search is necessary to clarify this issue. Overprescribing
may also be avoided by ensuring that general practitioners
are aware of the availability of public health advice to help
make decisions about prophylaxis. When publicity occurs
it is important to use the media to ensure that reliable in-
formation on the level of the risk of secondary cases is giv-
en to the public.
Further work is also necessary to investigate to what extent
potential barriers to contacts obtaining prophylaxis oper-
ate. Finally the use of structured recording forms will facil-
itate future audit of this important area of public health
practice.
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